Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

The following is a summary of “FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...